Global Cord Blood (NYSE:CO) and GS ACQUISITION /SH CL A (NYSE:GSAH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Valuation and Earnings
This table compares Global Cord Blood and GS ACQUISITION /SH CL A’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Global Cord Blood||$147.03 million||4.13||$43.38 million||N/A||N/A|
|GS ACQUISITION /SH CL A||N/A||N/A||$5.03 million||N/A||N/A|
This is a breakdown of current recommendations and price targets for Global Cord Blood and GS ACQUISITION /SH CL A, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Cord Blood||0||0||0||0||N/A|
|GS ACQUISITION /SH CL A||0||0||0||0||N/A|
This table compares Global Cord Blood and GS ACQUISITION /SH CL A’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Cord Blood||34.86%||10.88%||5.73%|
|GS ACQUISITION /SH CL A||N/A||198.32%||1.41%|
Institutional and Insider Ownership
16.3% of Global Cord Blood shares are held by institutional investors. Comparatively, 43.7% of GS ACQUISITION /SH CL A shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Global Cord Blood has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, GS ACQUISITION /SH CL A has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.
Global Cord Blood beats GS ACQUISITION /SH CL A on 5 of the 8 factors compared between the two stocks.
Global Cord Blood Company Profile
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).
GS ACQUISITION /SH CL A Company Profile
GS Acquisition Holdings Corp does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2016 and is based in New York, New York.
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.